Cardiovascular disease, statins and vitamin D.

Area of Science:

• Cardiology
• Preventive Medicine
• Pharmacology

Background:

• Cardiovascular disease (CVD) is the leading cause of premature death in the UK, imposing a significant economic burden.
• Reducing CVD burden is a governmental and healthcare priority.
• Conventional risk assessment tools may not accurately identify all at-risk individuals.

Purpose of the Study:

• To update nurses on advancements in cardiovascular risk assessment and management.
• To explore the utility of C-reactive protein (CRP) as a cardiovascular risk marker.
• To discuss evolving indications for statin therapy and the role of vitamin D.

Main Methods:

• Review of studies evaluating C-reactive protein (CRP) for cardiovascular risk prediction, including the Reynold's Risk Score.
• Analysis of the JUPITER trial and its sub-analyses on statin therapy in individuals with elevated CRP and normal cholesterol.
• Examination of the pleiotropic effects of statins, including their impact on CRP, endothelial repair, clotting, and vitamin D metabolism.

Main Results:

• The Reynold's Risk Score, utilizing CRP, reclassified cardiovascular risk in a significant proportion of men and women compared to conventional methods.
• The JUPITER trial demonstrated that rosuvastatin significantly reduced myocardial infarction, stroke, and venous thromboembolism in high-risk individuals with normal cholesterol but elevated CRP.
• Statins exhibit pleiotropic effects, including CRP reduction, enhanced endothelial repair, altered clotting factors, and improved vitamin D metabolism.

Conclusions:

• C-reactive protein (CRP) provides a more accurate assessment of cardiovascular risk than cholesterol alone.
• Elevated CRP may identify individuals who could benefit from statin therapy, even with normal cholesterol levels.
• The pleiotropic effects of statins, potentially linked to vitamin D, suggest vitamin D supplementation as a possible alternative or adjunct therapy for cardiovascular risk reduction.